Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Bremelanotide (Vyleesi) vs Degarelix (Firmagon)
An educational, source-based comparison of Bremelanotide (Vyleesi) and Degarelix (Firmagon) — how each peptide works, what it's researched for, and what to know before going deeper.
Melanocortin receptor agonist for hypoactive sexual desire disorder in premenopausal women.
Cyclic 7-amino-acid synthetic analog of α-MSH that activates melanocortin receptors (primarily MC4R) in the CNS, modulating sexual desire pathways.
- Acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women
- • FDA-approved.
- • Nausea, flushing, transient BP elevation common.
GnRH antagonist providing immediate testosterone suppression in prostate cancer.
Synthetic decapeptide GnRH receptor antagonist. Blocks GnRH receptors directly, producing rapid suppression of LH, FSH, and testosterone without the initial flare seen with agonists.
- Advanced prostate cancer
- • FDA-approved.
- • Injection-site reactions common.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Bremelanotide (Vyleesi) | RECONNECT trials | Obstetrics & Gynecology | 2019 | Improved desire and reduced distress vs placebo in premenopausal HSDD. |
| Degarelix (Firmagon) | Degarelix vs leuprolide CS21 trial | BJU International | 2008 | Faster testosterone suppression and no testosterone surge vs leuprolide. |
Side-effect & safety grid
- FDA-approved.
- Nausea, flushing, transient BP elevation common.
- FDA-approved.
- Injection-site reactions common.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Bremelanotide (Vyleesi) vs Degarelix (Firmagon) — Key differences
- Class: Bremelanotide (Vyleesi) is classified as Melanocortin Agonist · Sexual Health, while Degarelix (Firmagon) is GnRH Antagonist · Hormonal.
- Primary research focus: Bremelanotide (Vyleesi) — acquired, generalized hypoactive sexual desire disorder (hsdd) in premenopausal women; Degarelix (Firmagon) — advanced prostate cancer.
- Tag: FDA-Approved · Sexual Health vs FDA-Approved · Oncology.